Supernus Pharmaceuticals ROE 2011-2023 | SUPN
Current and historical return on equity (ROE) values for Supernus Pharmaceuticals (SUPN) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Supernus Pharmaceuticals ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2023-12-31 |
$0.00B |
$0.92B |
0.11% |
| 2023-09-30 |
$0.03B |
$0.91B |
2.75% |
| 2023-06-30 |
$0.04B |
$0.92B |
4.82% |
| 2023-03-31 |
$0.05B |
$0.91B |
5.96% |
| 2022-12-31 |
$0.06B |
$0.89B |
7.16% |
| 2022-09-30 |
$0.04B |
$0.85B |
4.55% |
| 2022-06-30 |
$0.06B |
$0.84B |
7.04% |
| 2022-03-31 |
$0.07B |
$0.83B |
9.14% |
| 2021-12-31 |
$0.05B |
$0.82B |
6.82% |
| 2021-09-30 |
$0.08B |
$0.81B |
10.73% |
| 2021-06-30 |
$0.10B |
$0.79B |
13.49% |
| 2021-03-31 |
$0.11B |
$0.75B |
15.59% |
| 2020-12-31 |
$0.13B |
$0.75B |
18.73% |
| 2020-09-30 |
$0.13B |
$0.71B |
20.13% |
| 2020-06-30 |
$0.12B |
$0.67B |
19.58% |
| 2020-03-31 |
$0.12B |
$0.61B |
20.45% |
| 2019-12-31 |
$0.11B |
$0.60B |
20.97% |
| 2019-09-30 |
$0.11B |
$0.56B |
21.06% |
| 2019-06-30 |
$0.11B |
$0.52B |
22.36% |
| 2019-03-31 |
$0.10B |
$0.48B |
23.61% |
| 2018-12-31 |
$0.11B |
$0.45B |
27.46% |
| 2018-09-30 |
$0.10B |
$0.42B |
27.67% |
| 2018-06-30 |
$0.09B |
$0.39B |
27.60% |
| 2018-03-31 |
$0.07B |
$0.35B |
26.55% |
| 2017-12-31 |
$0.06B |
$0.27B |
23.90% |
| 2017-09-30 |
$0.06B |
$0.25B |
25.94% |
| 2017-06-30 |
$0.10B |
$0.23B |
51.50% |
| 2017-03-31 |
$0.10B |
$0.21B |
56.39% |
| 2016-12-31 |
$0.09B |
$0.19B |
63.64% |
| 2016-09-30 |
$0.08B |
$0.17B |
71.79% |
| 2016-06-30 |
$0.03B |
$0.11B |
27.81% |
| 2016-03-31 |
$0.02B |
$0.10B |
21.43% |
| 2015-12-31 |
$0.01B |
$0.09B |
18.48% |
| 2015-09-30 |
$0.01B |
$0.08B |
17.19% |
| 2015-06-30 |
$0.01B |
$0.07B |
9.39% |
| 2015-03-31 |
$0.01B |
$0.06B |
13.79% |
| 2014-12-31 |
$-0.01B |
$0.04B |
-31.65% |
| 2014-09-30 |
$-0.04B |
$0.04B |
-112.98% |
| 2014-06-30 |
$-0.06B |
$0.03B |
-220.56% |
| 2014-03-31 |
$-0.09B |
$0.03B |
-323.64% |
| 2013-12-31 |
$-0.09B |
$0.03B |
-298.36% |
| 2013-09-30 |
$-0.08B |
$0.01B |
-225.85% |
| 2013-06-30 |
$-0.07B |
$0.04B |
-180.00% |
| 2013-03-31 |
$-0.06B |
$0.04B |
-135.80% |
| 2012-12-31 |
$-0.05B |
$0.06B |
-155.37% |
| 2012-09-30 |
$0.05B |
$0.03B |
272.22% |
| 2012-06-30 |
$0.05B |
$0.04B |
434.04% |
| 2012-03-31 |
$0.05B |
$0.00B |
2355.56% |
| 2011-12-31 |
$0.05B |
$0.01B |
2266.67% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.580B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
